China (Mainland)
Ticagrelor CAS NO.274693-27-5
- Min.Order: 0 Metric Ton
- Payment Terms:
- Product Details
Keywords
- (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazo
- AZD 6140
- AR-C 126532XX
Quick Details
- ProName: Ticagrelor
- CasNo: 274693-27-5
- Molecular Formula: C23H28F2N6O4S
- Appearance: white powder
- Application: API
- DeliveryTime: delivery after confirming an order
- PackAge: aluminium foil bag; drum; as per your ...
- ProductionCapacity: Metric Ton/Day
- Purity: 99.0%
- Storage: store in cool place. Keep container ti...
- Transportation: air transport, sea transport
- LimitNum: 0 Metric Ton
Superiority
Details
Trading information
| Product Name | Ticagrelor |
| Synonyms | (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol |
| CAS No. | 274693-27-5 |
| Molecular Formula | C23H28F2N6O4S |
| Molecular Weight | 522.57 |
| Appearance | white powder |
| Purity | 99.0% |
| Package | aluminium foil bag; drum |
| Payment Terms | L/C; D/A; D/P; T/T |
| Delivery | by air; by ship |
.jpg)
Sample Service
Considering the various needs of buyers, we provide small quantity sample to customers. You are welcomed to contact us for the detailed specifications of our APIs and pharmaceutical intermediates. Customers are also expected to confirm the type of freight transport and payment. Any more question please contact us directly.
.jpg)
Drug Interactions
| Drug | Interaction |
| Conivaptan | CYP3A4 Inhibitors (Strong) such as conivaptan may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor. Avoid use of ticagrelor in combination with strong CYP3A4 inhibitors. |
| Etravirine | Etravirine, when used concomitantly with ritonavir boosted ticagrelor, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy. |
| Lomitapide | Ticagrelor increases levels of lomitapide by affecting CYP3A4 enzyme metabolism. Concomitant therapy is contraindicated. |
| Lovastatin | Patients receiving more than 40 mg per day of lovastatin may be at increased risk of statin-related adverse effects. |
| Simvastatin | Patients receiving more than 40 mg per day of simvastatin may be at increased risk of statin-related adverse effects. |
Research and Development
Relying on advanced research platform and relative service of China Medicine City, Allyrise have made achievements in areas of antineoplastic, antiviral, diabetes drugs in recent years, with more than 20 kinds of APIs and advanced intermediates magnified in pilotscale experiment. The products are widely sold to famous pharmaceutical companies from around the world. To enhance our research and development level, Allyrise developed close cooperation with foreign pharmaceutical companies in customer synthesis and developing new drugs.
Technical Team
Jiangsu Allyrise Pharmaceutical Co., Ltd have a young and innovative technician team with average age of 29 and backgrounds of famous universerties. We have rich experience in lab research and pilot scale experiment, laying the foundation for further personnel cultivation.
.jpg)
Escrow Service
Allyrise accept Escrow Service which is based on Lookchem as a third-party. Both buyer and seller are guranteed that their transaction is simple and secure.
.jpg)
![AcetaMide, N-[(1R)-1-(4-broMophenyl)ethyl]-2,2,2-trifluoro-](http://file1.lookchem.com/300w/substances/2022-02-21-10/1ff12cc5-0d08-4ffa-a802-dc535dc9ab1d.png)
![(αR)-α-[(1R)-1-Aminoethyl]-α-(2,4-difluorophenyl)-1H-1,2,4-triazole-1-ethanol Hydrochloride](http://file1.lookchem.com/cas/2024/03/06/1391468-05-5.jpg)
